TrialInternational journal of clinical practice2021

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.

Francis Berenbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.